Neurocrine Biosciences, Inc. (NBIX)
NASDAQ: NBIX · IEX Real-Time Price · USD
145.69
+1.55 (1.08%)
At close: Jul 19, 2024, 4:00 PM
158.45
+12.76 (8.76%)
Pre-market: Jul 22, 2024, 4:08 AM EDT
Neurocrine Biosciences Revenue
Neurocrine Biosciences had revenue of $1.98B in the twelve months ending March 31, 2024, with 23.99% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $515.30M with 22.57% year-over-year growth. In the year 2023, Neurocrine Biosciences had annual revenue of $1.89B with 26.76% growth.
Revenue (ttm)
$1.98B
Revenue Growth
+23.99%
P/S Ratio
7.40
Revenue / Employee
$1,415,714
Employees
1,400
Market Cap
14.66B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 1.89B | 398.40M | 26.76% |
Dec 31, 2022 | 1.49B | 355.20M | 31.34% |
Dec 31, 2021 | 1.13B | 87.60M | 8.38% |
Dec 31, 2020 | 1.05B | 257.80M | 32.71% |
Dec 31, 2019 | 788.10M | 336.90M | 74.67% |
Dec 31, 2018 | 451.20M | 289.57M | 179.16% |
Dec 31, 2017 | 161.63M | 146.63M | 977.51% |
Dec 31, 2016 | 15.00M | -4.77M | -24.12% |
Dec 31, 2015 | 19.77M | - | - |
Dec 31, 2014 | 0 | - | - |
Dec 31, 2013 | 2.92M | -50.22M | -94.51% |
Dec 31, 2012 | 53.14M | -24.27M | -31.36% |
Dec 31, 2011 | 77.41M | 43.91M | 131.08% |
Dec 31, 2010 | 33.50M | 30.55M | 1,034.47% |
Dec 31, 2009 | 2.95M | -1.02M | -25.71% |
Dec 31, 2008 | 3.98M | 2.75M | 224.75% |
Dec 31, 2007 | 1.22M | -38.01M | -96.88% |
Dec 31, 2006 | 39.23M | -84.66M | -68.33% |
Dec 31, 2005 | 123.89M | 38.71M | 45.45% |
Dec 31, 2004 | 85.18M | -53.90M | -38.76% |
Dec 31, 2003 | 139.08M | 121.03M | 670.73% |
Dec 31, 2002 | 18.05M | -23.20M | -56.25% |
Dec 31, 2001 | 41.24M | 26.65M | 182.71% |
Dec 31, 2000 | 14.59M | -2.20M | -13.12% |
Dec 31, 1999 | 16.79M | 754.00K | 4.70% |
Dec 31, 1998 | 16.04M | -10.11M | -38.66% |
Dec 31, 1997 | 26.14M | 6.93M | 36.05% |
Dec 31, 1996 | 19.22M | 13.11M | 214.72% |
Dec 31, 1995 | 6.11M | 5.94M | 3,679.88% |
Dec 31, 1994 | 161.53K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Molina Healthcare | 35.85B |
Viatris | 15.36B |
Quest Diagnostics | 9.29B |
Incyte | 3.77B |
BeiGene | 2.76B |
Revvity | 2.73B |
United Therapeutics | 2.50B |
BioMarin Pharmaceutical | 2.47B |
NBIX News
- 2 days ago - Neurocrine's Growing Sales, Profits Attracting Big Money - FXEmpire
- 3 days ago - Neurocrine Biosciences Launches INGREZZA® SPRINKLE (valbenazine) Capsules to Ease Administration for Patients Experiencing Dysphagia or Difficulty Swallowing - PRNewsWire
- 10 days ago - Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2024 Financial Results - PRNewsWire
- 21 days ago - Neurocrine Biosciences Announces U.S. FDA Accepts New Drug Applications and Grants Priority Review for Crinecerfont for Pediatric and Adult Patients with CAH - PRNewsWire
- 6 weeks ago - Neurocrine Biosciences Presented CAHtalyst™ Phase 3 Pediatric and Adult Studies, CAHtalog™ Registry and Disease- and Glucocorticoid-Related Comorbidities Data in CAH at ENDO 2024 - PRNewsWire
- 7 weeks ago - Neurocrine Biosciences Announces Publication of Primary CAHtalyst™ Pediatric Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine - PRNewsWire
- 7 weeks ago - Neurocrine Biosciences Announces Publication of Primary CAHtalyst™ Adult Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine - PRNewsWire
- 7 weeks ago - Neurocrine Biosciences to Participate at Investor Conferences in June - PRNewsWire